This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.
Subjects with MDD or PTSD will have a series of six ketamine infusions over two to three weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
ketamine infusion
Wild Health
Lexington, Kentucky, United States
RECRUITINGEpigenetic Age
DNA Methylation-derived epigenetic age
Time frame: Biological age will be compared from baseline to study completion, an average of five weeks
Severity of Illness and baseline epigenetic age
Assess if severity of illness prior to treatment is associated with biological age before treatment
Time frame: Assessment will evaluate the correlation of data collected at baseline with data from after treatment is completed, on average five weeks
Severity of Illness and post-treatment epigenetic age
Assess if severity of illness, as measured by PHQ-9 (Patient Health Questionnaire-9) or PCL-5 (PTSD Checklist for DSM 5) prior to treatment is associated with biological age after treatment
Time frame: Assessment will evaluate the correlation of data collected at baseline with biological age assessed after treatment is complete, on average five weeks
Degree of Treatment Response
Assess if degree of treatment response to ketamine infusion, as measured by PHQ-9 (Patient Health Questionnaire-9) or PCL-5 (PTSD Checklist for DSM 5), is associated with change in biological age
Time frame: Assessment will compare the difference in PHQ-9/PCL-5 scores from baseline to after treatment with change in biological age from baseline to post-treartment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.